At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 226 enrolled
Drug / intervention
lamotrigine, 300 mg/day +1 moredrug
Likely dose
lamotrigine, 300 mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures
In Brief
A Phase 3 clinical trial evaluating lamotrigine, 300 mg/day and lamotrigine, 250 mg/day for Epilepsy, Partial. Completed, enrolled 226 participants across 103 sites in 8 countries.
Detailed Summary
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy, Partial
CountriesArgentina, Chile, Costa Rica, Puerto Rico, Russia, South Korea, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedJul 2006
Primary CompletionNov 2008
TodayJul 2026
First PostedJul 21, 2006
Enrollment StartMay 1, 2006
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 19.9 years ago
Interventions
lamotrigine, 300 mg/daydrug
300 mg/day
lamotrigine, 250 mg/daydrug
250 mg/day